Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine
type: Thing
description: clinical trial
additional property: PropertyValue
  property ID: P31
  value: clinical trial
additional property: PropertyValue
  property ID: P580
  value: June 22, 2020
additional property: PropertyValue
  property ID: P582
  value: July 21, 2021
additional property: PropertyValue
  property ID: P1132
  value: +50
additional property: PropertyValue
  property ID: P1476
  value: A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age
additional property: PropertyValue
  property ID: P2899
  value: +18
additional property: PropertyValue
  property ID: P3098
  value: NCT04445194
additional property: PropertyValue
  property ID: P4135
  value: +59
additional property: PropertyValue
  property ID: P6099
  value: phase I clinical trial
additional property: PropertyValue
  property ID: P6153
  value: Chongqing Medical University
additional property: PropertyValue
  property ID: P8005
  value: recruiting
additional property: PropertyValue
  property ID: P8363
  value: interventional study
confidence:
  popularity graph score:
    score: 0.0
    score pct: 0
    tier: long_tail
    components:
      sitelinks: 0
      sitelinks norm: 0.0
      unique citations: 0
      unique citations norm: 0.0
      monthly pageviews: 0
      monthly pageviews norm: 0.0
  sitelinks: 0
  unique citations: 0
  monthly pageviews: 0
  yearly pageviews: 0
  tier: long_tail
claims:
  P31:
    value: Q30612
    source count: 0
    confidence: 0.0
    value label: clinical trial
  P580:
    value: +2020-06-22T00:00:00Z
    source count: 0
    confidence: 0.0
  P582:
    value: +2021-07-21T00:00:00Z
    source count: 0
    confidence: 0.0
  P1132:
    value:
      unit: 1
      amount: +50
    source count: 0
    confidence: 0.0
  P1476:
    value: A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age
    source count: 0
    confidence: 0.0
  P2899:
    value:
      unit: http://www.wikidata.org/entity/Q577
      amount: +18
    source count: 0
    confidence: 0.0
  P3098:
    value: NCT04445194
    source count: 0
    confidence: 0.0
  P4135:
    value:
      unit: http://www.wikidata.org/entity/Q577
      amount: +59
    source count: 0
    confidence: 0.0
  P6099:
    value: Q5452194
    source count: 0
    confidence: 0.0
    value label: phase I clinical trial
  P6153:
    value: Q5104661
    source count: 0
    confidence: 0.0
    value label: Chongqing Medical University
  P8005:
    value: Q76649708
    source count: 0
    confidence: 0.0
    value label: recruiting
  P8363:
    value: Q9164018
    source count: 0
    confidence: 0.0
    value label: interventional study
meta:
  wikidata id: Q97461865
  domain: clinical_trial
  level: standard
  html url: https://4ort.xyz/entity/phase-i-clinical-study-of-recombinant-novel-coronavirus-vaccine
  markdown url: https://4ort.xyz/entity/phase-i-clinical-study-of-recombinant-novel-coronavirus-vaccine.md
  facts url summary: https://4ort.xyz/entity/phase-i-clinical-study-of-recombinant-novel-coronavirus-vaccine/facts.json
  facts url standard: https://4ort.xyz/entity/phase-i-clinical-study-of-recombinant-novel-coronavirus-vaccine/facts.json
  facts url full: https://4ort.xyz/entity/phase-i-clinical-study-of-recombinant-novel-coronavirus-vaccine/facts.json
  data source: Wikidata (CC0 / public domain)
  license: https://creativecommons.org/publicdomain/zero/1.0/
  api version: v1
  served at: 2026-08-04T03:39:34.042794Z
  entity updated at: 2026-05-03T18:28:36.114423+00:00Z
  entity created at: 2026-05-03T14:30:32.950114+00:00Z